Prenatal maternal paroxetine treatment and neonatal mortality in the rat: A preliminary study

Neonatology

Volumn 93, Issue 1, 2007, Pages 52-55

  Van Den Hove, Daniël L A ^a,c   Blanco, Carlos E ^b   Scheepens, Arjan ^a,b   Desbonnet, Lieve ^a   Myint, Aye Mu ^a   Leonard, Brian E ^a   Prickaerts, Jos ^a   Steinbusch, Harry W M ^a  

^a European Graduate School of Neuroscience   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Antidepressants; Mortality; Neonatal withdrawal syndrome; Pregnancy; Prenatal stress; Selective serotonin reuptake inhibitors; Serotonin syndrome

Indexed keywords

PAROXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIRTH WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MATERNAL STRESS; MATERNAL TREATMENT; NEWBORN MORTALITY; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; FEMALE; MALE; PAROXETINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, INBRED F344; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL;

RATTUS;

EID: 37249059258     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000106433     Document Type: Article

References (13)

1. Huizink AC, Mulder EJ, Buitelaar JK: Prenatal stress and risk for psychopathology: specific effects or induction of general susceptibility? Psychol Bull 2004;130:115-142.
2. Van den Bergh BRH, Mulder EJH, Mennes M, Glover V: Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci Biobehav Rev 2005;29:237-258.
3. Robins LN, Regier DA (eds): Psychiatric Disorders in America: the Epidemiologic Catchment Area Study. New York, Free Press, 1991.
4. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB: Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96.
5. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D: Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-996.
6. Van den Hove DL, Blanco CE, Aendekerk B, Desbonnet L, Bruschettini M, Steinbusch HP, Prickaerts J, Steinbusch HW: Prenatal restraint stress and long-term affective consequences. Dev Neurosci 2005;27:313-320.
7. Pineyro G, Blier P, Dennis T, de Montigny C: Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 1994;14:3036-3047.
8. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R: Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482.
9. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-2383.
10. Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S: Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol 2005;19:554-557.
11. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M: Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:961-966.
12. Hobel C, Culhane J: Role of psychosocial and nutritional stress on poor pregnancy outcome. J Nutr 2003;133:1709S-1717S.
13. Aghajafari F, Murphy K, Matthews S, Ohlsson A, Amankwah K, Hannah M: Repeated doses of antenatal corticosteroids in animals: a systematic review. Am J Obstet Gynecol 2002;186:843-849.